Table 2.

Adverse Events at Least Possibly Related to Treatment (n=32 patients)

	Any Grade		Grade 3-5
Treatment Related
Any	27	84.4%	16	50.0%
Serious	12	37.5%	11	34.4%
Led to discontinuation	10	31.3%	8	25.0%
Led to deatd	0	0.0%	0	0.0%
Occurred in ≥5% of patients
Fatigue	9	28.1%	1	3.1%
Nausea	9	28.1%	0	0.0%
Vomiting	8	25.0%	1	3.1%
Alkaline phosphatase increased	7	21.9%	2	6.3%
Anorexia	7	21.9%	0	0.0%
Lymphocyte count decreased	5	15.6%	1	3.1%
Platelet count decreased	5	15.6%	0	0.0%
Anemia	4	12.5%	2	6.3%
Dyspnea	4	12.5%	1	3.1%
Generalized muscle weakness	4	12.5%	0	0.0%
Weight loss	4	12.5%	0	0.0%
Hyperglycemia	3	9.4%	1	3.1%
Dizziness	3	9.4%	0	0.0%
Dry skin	3	9.4%	0	0.0%
Hypoalbuminemia	3	9.4%	0	0.0%
Neutrophil count decreased	3	9.4%	0	0.0%
White blood cell decreased	3	9.4%	0	0.0%
Autoimmune disorder	2	6.3%	2	6.3%
Sepsis	2	6.3%	2	6.3%
Acute kidney injury	2	6.3%	1	3.1%
Endocrine disorders-Other	2	6.3%	1	3.1%
Sinusitis	2	6.3%	1	3.1%
Blurred vision	2	6.3%	0	0.0%
Constipation	2	6.3%	0	0.0%
Dry mouth	2	6.3%	0	0.0%
Dysgeusia	2	6.3%	0	0.0%
Edema limbs	2	6.3%	0	0.0%
Fever	2	6.3%	0	0.0%
Hypertension	2	6.3%	0	0.0%
Hypocalcemia	2	6.3%	0	0.0%
Hypokalemia	2	6.3%	0	0.0%
Proteinuria	2	6.3%	0	0.0%
Skin/subq tissue ds-Other	2	6.3%	0	0.0%
Immune-mediated
Any	23	71.9%	12	37.5%
Hypothyroidism	10	31.3%	0	0.0%
AST increased	8	25.0%	2	6.3%
Artdralgia	7	21.9%	1	3.1%
Diarrhea	7	21.9%	1	3.1%
Pruritus	7	21.9%	0	0.0%
Rash maculo-papular	5	15.6%	1	3.1%
ALT increased	4	12.5%	3	9.4%
Lipase increased	3	9.4%	2	6.3%
Hyperthyroidism	3	9.4%	0	0.0%
Infusion related reaction	3	9.4%	0	0.0%
Encephalopathy	2	6.3%	2	6.3%
Colitis	2	6.3%	1	3.1%
Pancreatitis	2	6.3%	1	3.1%
Retinopathy	1	3.1%	1	3.1%
Blood bilirubin increased	1	3.1%	0	0.0%